1 |
Carpenter G. 1987. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem. 56, 881-914
DOI
ScienceOn
|
2 |
Harris, A. J. 1985. DNA repair: relationship to drug and radiation resistance, metastasis and growth factors. Int. J. Radiat. BioI. Relat. Stud. Phys. Chem. Med. 45, 675-690
|
3 |
Usmani, B. A., J. Lunec and G. V. Sherbet. 1993. DNA repair and repair fidelity in metastatic variants of the B16 murine melanoma. J. Cell Biochem. 51, 336-344
DOI
ScienceOn
|
4 |
Yang, S. H., A. Nussenzweig, W. H. Yang, D. Kim and G. C. Li. 1996. Cloning and characterization of Rat Ku70: Involvement of Ku autoantigen in the heat-shock response. Rad. Res. 146, 603-611
DOI
ScienceOn
|
5 |
Kim, S. H., D. Kim, J. S. Han, C. S. Jeong, B. S. Chung, C. D. Kang and G. C. Li. 1999. Ku autoantigen affects the susceptibility to anticancer drugs. Cancer Res. 59, 4012-4017
|
6 |
Chen, W. S., C. S. Lazar, M. Poenie, R. Y. Tsien, G. N. Gill and M.G. Rosenfeld. 1987. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature 328, 820-823
DOI
ScienceOn
|
7 |
Todaro, G. J., C. Fryling and J. E. De Larco. 1980. Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc. NatI. Acad. Sci. USA 77, 5258-5262
|
8 |
Hu, G., W. Liu, J. Mendelsohn, J. M. Ellis, R. Radinsky, M. Andreeff and A. B. Deisseroth. 1997. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. NatI. Cancer Inst. 89, 1271-1276
DOI
ScienceOn
|
9 |
Iihara, K., H. Shiozaki, H. Tahara, K. Kobayashi, M. Inoue, S. Tamura, M. Miyata, H. Oka, Y. Doki, and T. Mori. 1993. Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer 71, 2902-2909
DOI
ScienceOn
|
10 |
Grandis, J. R., M. F. Melhem, W. E. Gooding, R. Day, V. A. Holst, M. M. Wagener, S. D. Drenning and D. J. Tweardy. 1998. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. NatI. Cancer Inst. 90, 824-832
DOI
ScienceOn
|
11 |
Klijn, J. G., P. M. Berns, P. J. Schmitz and J. A. Foekens. 1992. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev. 13, 3-17
|
12 |
Dickstein, B. M., K. Wosikowski and S. E. Bates. 1995. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol. Cell Endocrinol. 110, 205-211
DOI
ScienceOn
|
13 |
Balaban, N., J. Moni, M. Shannon, J. Dang, E. Murphy and T. Goldkom. 1996. The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim. Biophys. Acta 1314, 147-156
DOI
ScienceOn
|
14 |
Webb, C. P. and G. F. 2000. Vande Woude. Genes that regulate metastasis and angiogenesis. J. Neurooncol. 50, 71-87
DOI
ScienceOn
|
15 |
Wei, Q., J. Cheng, K. Xie, C. D. Bucana and Z. Dong. 1997. Direct correlation between DNA repair capacity and metastatic potential of K-1735 murine melanoma cells. J. Invest. Dermatol. 105, 3-6
|
16 |
Liang, Y., S. McDonnell and M. Clynes. 2002. Examining the relationship between cancer invasion/metastasis and drug resistance. Curr. Cancer Drug Targets 2, 257-277
DOI
ScienceOn
|
17 |
Kim, S. H., J. H. Um, D. W. Kim, B. H. Kwon, D. W. Kim, B. S. Chung and C. D. Kang. 2000. Potentiation of chemosensitivity in multidrug-resistant human leukemia CEM cells by inhibition of DNA-dependent protein kinase using wortmannin. Leuk. Res. 11, 917-925
|
18 |
Sartor. C. J. 2000. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family. Semin. Oncol. 27, 15-20
|
19 |
Usmani, B. A. and G. V. Sherbet. 1996. Homologous recombination in variants of the B16 murine melanoma with reference to their metastatic potential. J. Cell Biochem. 61, 1-8
DOI
|
20 |
Baselga, J. 2002. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J. Clin. Oncol. 20, 2217-2219
|
21 |
Nakajima, M., K. Kashiwagi, J. Ohta, S. Furukawa, K. Hayashi, T. Kawashima and Y. Hayashi. 1994. Nerve growth factor and epidermal growth factor rescue PC12 cells from programmed cell death induced by etoposide: distinct modes of protection against cell death by growth factors and a protein-synthesis inhibitor. Neurosci. Lett. 176, 161-164
DOI
ScienceOn
|
22 |
Milas, J., K. Mason, N. Hunter, S. Petersen, M. Yamakawa, K. Ang, J. Mendelsohn and Z. Fan. 2000. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 6, 701-708
|
23 |
Solorzano, C. C., C. H. Baker, R. Tsan, P. Traxler, P. Cohen, E. Buchdunger, J. J. Killion and J. J. Fidler. 2001. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin. Cancer Res. 7, 2563-2572
|
24 |
Walker, J. R., R. A. Corpina and J. Goldberg. 2001. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature 412, 607-614
DOI
ScienceOn
|
25 |
Sweeney, P., T. Karashima, S. J. Kim, D. Kedar, B. Mian, S. Huang, C. Baker, Z. Fan, D. J. Hicklin, C. A Pettaway and C. P. Dinney. 2002. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin. Cancer Res. 5, 2714-2724
|
26 |
Sana, H., Y. Veda, N. Takakura, G. Takemura, T. Doi, H. Kataoka, T. Murayama, Y. Xu, T. Sudo, S. Nishikawa, S. Nishikawa, H. Fujiwara, T. Kita and M. Yokode. 2002. Blockade of platelet-derived growth factor receptor-beta pathway induces apoptosis of vascular endothelial cells and disrupts glomerular capillary formation in neonatal mice. Am. J. Pathol. 161, 135-143
DOI
ScienceOn
|
27 |
Mendelsohn, J. 1997. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 3, 2703-2707
|
28 |
Bharti, A., S. K. Kraeft, M. Gounder, P. Pandey, S. Jin, Z. M. Yuan, S. P. Lees-Miller, R. Weichselbaum, D. Weaver, L.B. Chen, D. Kufe and S. Kharbanda. 1998. Inactivation of DNA-dependent protein kinase by protein kinase C delta: implications for apoptosis. Mol. Cell BioI. 18, 6719-6728
|
29 |
Lu, Z., G. Jiang, P. Blume-Jensen and Hunter, T. 2001. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol. Cell BioI. 21, 4016-4031
DOI
ScienceOn
|
30 |
Liang, Y., P. Meleady, J. Cleary, S. McDonnell, L. Connolly and M. CIynes. 2001. Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur. J. Cancer 37, 1041-1052
DOI
ScienceOn
|
31 |
Fan, Z., J. Baselga, H. Masui and J. Mendelsohn. 1993. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well-established A431 cell xenografts. Cancer Res. 53, 4637-4642
|
32 |
Schmidt, M and R B. Lichtner. 2002. EGF receptor targeting in therapy-resistant human tumors. Drug Resist. Updat. 5, 11-18
DOI
ScienceOn
|
33 |
Huang. S. M. and P. M. Harari. 2000. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6, 2166-2174
|
34 |
Bandyopadhyay, D., M. MandaI, J. Adam, J. Mendelsohn and R Kumar. 1998. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J. BioI. Chem. 273, 1568-1573
DOI
ScienceOn
|